FPCPP, A Division of CFHC

Family Planning Cooperative Purchasing Program

A non-profit purchasing collaborative for health care & community organizations

March 01, 2012

An Important Drug Recall from Glenmark Generics

We would like to inform you of the important Drug Recall on Norgestimate and Ethinyl Estradiol Tablets USP sent from Glenmark-Generics. 

Glenmark-Generics is recalling seven (7) lots of Norgestimate and Ethinyl Estradiol Tablets USP, 0.18 mg/0.035 mg, 0.215 mg/0.035 mg, 0.25 mg/0.035 mg.  Glenmark Generics issued a voluntary, nationwide, consumer-level recall because of packaging error, where select blisters were rotated 180 degrees within the card, reversing the weekly tablet orientation and making the lot number and expiry date visible only in the outer pouch.  Any blister for which the lot number and expiry date is not visible is subject to recall.

These tablets were manufactured and packaged by Glenmark Generics Ltd. India. and are distributed by Glenmark Generics Inc.USA.  This product was distributed to wholesalers and retail pharmacies nationwide between September 21, 2011 and December 30, 2011.

Lot numbers of affected packs of Norgestimate and Ethinyl Estradiol Tablets USP, 0.18 mg/0.035 mg, 0.215 mg, 0.035 mg, 0.25 mg/0.035 mg, (Generic) are as follows:

 

NDC                                            Lot Nos                            Expiration

68462-565-29                              04110101                          7/31/2013

                                                  04110106                          7/31/2013

                                                  04110107                          7/31/2013

                                                  04110114                          8/31/2013

                                                  04110124                          8/31/2013

                                                  04110129                          8/31/2013

                                                  04110134                          9/30/2013

Any adverse events that may be related to the use of these products should be reported to Glenmark Generics, Inc., USA at 1-(888) 721-7115 (8 AM to 5 PM Mon-Fri EST) or to FDA’s Med Watch Program either online, by regular mail or by fax.

 

   Online:                  www.fda.gov/medwatch/report.htm

Regular Mail:            Use postage-paid, pre-addresses Form FDA 3500 available at: www.fda.gov/MedWatch/getforms.htm. Mail to the address on the pre-addressed form.

    Fax:                     1-800-FDA-0178

 

March 1, 2012 in Glenmark-Generics , News , Oral Contraceptives , Pharmaceutical Products , Pharmaceuticals , Vendors | Permalink | TrackBack (0)

January 17, 2012

An Important Drug Recall - LO/OVRAL-28 and Norgestrel 0.3mg/Ethinyl Estradiol 0.03mg Tablets

Following is a Pfizer generated document we received on Friday, January 13, 2012:

 

Pfizer Inc. is recalling multiple lots of LO/OVRAL - 28 Tablets and Norgestrel 0.3mg/Ethinyl Estradiol 0.03mgTablets manufactured and packaged by Pfizer, and distributed and commercialized by Akrimax Pharmaceuticals, LLC (see below for lot numbers and expiration dates).  Please note that these products are labeled with Akrimax labeling.  Pfizer Inc. voluntarily initiated this recall when it was determined that some blister packs may contain an inexact count of placebo or active ingredient tablets.  Please note that use of this product is not likely to cause adverse health consequences.

 

FEDERAL REGULATIONS REQUIRE THAT YOU RESPOND TO THIS RECALL, EVEN IF YOU DO NOT HAVE THE RECALLED PRODUCT. TO RESPOND, PLEASE CONTACT STERICYCLE INC. AT 1(800)-805-3093 WITHIN FIVE (5) BUSINESS DAYS.

 

The recall of LO/OVRAL - 28 Tablets and Norgestrel 0.3mg/Ethinyl Estradiol 0.03 mg Tablets is being conducted to the retail level.

 

Records indicate that you may have received shipment of affected lots between January 2011 and December 2011.  Please check your stock immediately against the table below.  If you have any of the affected products in your inventory, please stop distribution and promptly return to Stericycle Inc. 2670 Executive Drive, Suite A Indianapolis, IN 46241: Attn: Event 2568.  Please contact Stericycle Inc. at (800) 805-3093 if you require the pre-paid UPS labels.  If you have any medical inquiries regarding these products, please contact Akrimax Medical Information at 1(877)509-3935 (8 AM to 7 PM Mon-Fri CST).

 

If you have further distributed the lots to the retail level, please conduct a sub-recall and communicate this recall information to those accounts immediately.  Please request that they immediately cease distribution of the affected lots and promptly return the product directly to the above address.  If they have inventory of the affected product, they can contact Stericycle Inc. at (800) 805-3093 to obtain pre-paid shipping labels for product return.  Further authorization is not required for product return.  Reimbursement for the returned product will be made by credit memorandum.  If you have any questions regarding the reimbursement, please contact your Akrimax Customer Service Representative at 1(877) 509-3935 (8 AM to 7 PM Mon-Fri CST).

 

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.  We appreciate your immediate attention and cooperation to this matter.

 

LO/OVRAL® - 28 

LOT#         Expiration Date

E15678        8/31/2013

E15679        8/31/2013

E15686        8/31/2013

   E15687        1/31/2014   

E15690        1/31/2014

E15698        1/31/2014

E15700        2/28/2014

E80434        7/31/2013

E80438        8/31/2013

F36908        2/28/2014

F36909        2/28/2014

F43915        3/31/2014

F43926        3/31/2014

F43927        3/31/2014

 

NORGESTREL 0.3MG/ETHINYL ESTRADIOL 0.03 MG

LOT#         Expiration Date

E15677        8/31/2013

E15704        1/31/2014

E15706        1/31/2014

E80440        8/31/2013

F16388        1/31/2014

F16390        2/28/2014

F22132        2/28/2014

F31330        2/28/2014

F36911        3/31/2014

F36913        3/31/2014

F43924        3/31/2014

F43925        3/31/2014

F43934        3/31/2014

F53238        3/31/2014

January 17, 2012 in Contraception , Cooperative Updates , Health Care , Oral Contraceptives , Pharmaceutical Products , Pharmaceuticals , Sales , Women’s Health | Permalink | TrackBack (0)

October 19, 2011

Daily-Vite from R&S Northeast

Daily-Vite from R&S Northeast

Daily Multiple Vitamin Supplement

 

Save 10% off your first purchase of 12 Bottles of Daily-Vites.

Folic Acid is a B vitamin that helps a baby's neural tube grow healthy during pregnancy.  The neural tube will become a baby's brain and spinal cord.  But if the neural tube doesn't close the way it should, it can cause a very serious birth defect called a neural tube defect (NTD).

 

  • Folic Acid helps prevent certain brain defects.
  • Folic acid works if taken before and during early pregnancy.
  • Take a daily multivitamin with 400 micrograms of folic acid.

 

 

R&S DailyViteRS

Please contact your R&S Sales Representative  for pricing.

Pennsylvania (800) 262-7770

Ohio (866) 994-7472

Kentucky (866) 228-9758

 

Be sure to mention that you are a member of the Cooperative Purchasing Program!



October 19, 2011 in Coupons , Health Care , Pharmaceutical Products , Pharmaceuticals , R&S Northeast , Sales , Teen Pregnancy , Vendors , Women’s Health | Permalink | TrackBack (0)

January 07, 2009

Merck Seeks FDA Approval for HPV Vaccine Use in Boys, Young Men

Public Release Date: 6-January-2009

Merck is seeking FDA approval for the use of its human papillomavirus vaccine, Gardasil, for boys and young men ages nine to 26, the Wall Street Journal reports. Merck is seeking the approval for the prevention of male genital warts and other lesions, for which Gardasil was shown effective in recent studies, according to a Merck spokesperson.

Continue reading "Merck Seeks FDA Approval for HPV Vaccine Use in Boys, Young Men"

January 7, 2009 in Pharmaceutical Products , Pharmaceuticals , STD | Permalink | TrackBack (0)

September 30, 2008

IMPORTANT: Product Discontinuation Notice From Ortho Women's Health & Urology

Logo_4

URGENT

PRODUCT DISCONTINUATION

MODICON Clinic

September 30, 2008

Dear Customer:

Ortho Women’s Health & Urology is discontinuing the “clinic” package of MODICON NDC 00062-1714-20 effective immediately. The “trade” package of MODICON NDC 00062-1714-15 continues to be available and should be ordered in place of NDC 00062-1714-20.

DISCONTINUED

PRODUCT:  MODICON CLINIC 

NDC CODE:  00062-1714-20

PRODUCT DESCRIPTION:  Veridate Dispenser Packs

AVAILABLE

PRODUCT:  MODICON TRADE

NDC CODE: 00062-1714-15

PRODUCT DESCRIPTION:  DIALPAK Dispenser Packs

We apologize for any inconvenience this may cause you.  If there are any questions, please contact JOM Pharmaceutical Service’s Customer Service Department at:
800-631-5273. 

Regards,

April Fisher
Strategic Business Group
Ortho-McNeil Janssen Pharmaceuticals, Inc.

September 30, 2008 in Pharmaceutical Products , Pharmaceuticals , Vendors | Permalink | TrackBack (0)

September 16, 2008

2008-09 Flu Vaccine Discounts Available for FPCPP/CPN Members!!

We have great news for our members! Just in time for flu season and "Get Ready Day," our friends over at Anda have agreed to give Cooperative Purchasing Program members deep discounts on Afluria!

The price schedule looks like this:

10 dose Vial (5 ml)          $82.35

10 pack Pre-fill syringe    $113.95

Click HERE to access the order form!

Please call our Membership Coordinator, Julia Shebby, at 213-386-5614 x4558 or send an email to coop@cfhc.org for membership details.

September 16, 2008 in Pharmaceutical Products , Pharmaceuticals , Vendors , Watson | Permalink | TrackBack (0)

March 26, 2008

Study Examines Diaphragm Use, Acceptability for STI Prevention

Public Release Date: 20-March-2008

Abstract of "Evidence-Based Planning of a Randomized Controlled Trial on Diaphragm Use for Prevention of Sexually Transmitted Infections," Behets et al. Sexually Transmitted Diseases, March 2008.

Frieda Behets of the University of North Carolina-Chapel Hill and colleagues examined whether commercial sex workers in Madagascar would accept and use a diaphragm to prevent sexually transmitted infections in an effort to determine potential obstacles in future research on the effectiveness of a diaphragm for use in STI prevention.

Continue reading "Study Examines Diaphragm Use, Acceptability for STI Prevention"

March 26, 2008 in Barriers , Contraception , Contraceptives , Medical Access , Pharmaceutical Products , Women’s Health | Permalink | TrackBack (0)

February 13, 2008

Kroger Launches Discount Drug Program, Includes Generic Birth Control

Public Release Date: 7-February-2008

On Wednesday, the Cincinnati-based Kroger announced that it will begin selling 30-day supplies of more than 300 generic prescription drugs, including birth control pills, at significant discounts at participating pharmacies nationwide, the Atlanta Journal-Constitution reports.

Continue reading "Kroger Launches Discount Drug Program, Includes Generic Birth Control"

February 13, 2008 in Contraception , Contraceptives , News , Oral Contraceptives , Pharmaceutical Products , Women’s Health | Permalink | TrackBack (0)

January 16, 2008

FemCap's HIV Prevention Presentation

Aids_pandemic_2Alfred Shihata of FemCap gave a presentation at the HIV Prevention Conference in Atlana last month, and was kind enough to share it with us!

Click here to see the presentation!

January 16, 2008 in Barriers , Contraception , Contraceptives , Educational , Femcap , Pharmaceutical Products , Vendors , Women’s Health | Permalink | TrackBack (0)

December 26, 2007

FDA To Require Vaginal Contraceptive Products Containing Spermicide Nonoxynol-9 To Carry Warning That Products Do Not Protect Against STIs

Public Release Date: 20-December-2007

FDA on Dec. 19 issued a final rule that will require over-the-counter vaginal contraceptive products containing the spermicide nonoxynol-9 to include warning statements and other labeling information to clarify that the products do not prevent sexually transmitted infections, including HIV, Reuters reports.

Continue reading "FDA To Require Vaginal Contraceptive Products Containing Spermicide Nonoxynol-9 To Carry Warning That Products Do Not Protect Against STIs"

December 26, 2007 in Pharmaceutical Products | Permalink | TrackBack (0)